Tagged with Switzerland

Health Pascal Strupler of the Federal Office of Public Health discusses the intricacies of the Swiss healthcare system, highlighting the importance of the NCD in health prevention, strategies for cost reduction, and his support for open dialogue between healthcare stakeholders in order to provide the public with an accessible and efficient…

Pharma Olaf Weppner, General Manager of AbbVie Switzerland, highlights AbbVie’s intended foray into oncology, the importance of immunology to the group, the challenges and opportunities of the Swiss market and his own motivations for working in the industry. Mr. Weppner, you were appointed General Manager of AbbVie Switzerland less than a…

Switzerland Dr. Catherine Chammartin of the Swiss Federal Institute of Intellectual Property (IPI) describes the strong elements of an IP system and its contributions to innovation within Switzerland. The IPI registers intellectual property, advises on policy, provides IP services to the community, and is involved in educational endeavors. Could you start…

Pharma Tuomo Pätsi, President of the EMEA region for Celgene, talks about marking the tenth anniversary of Switzerland as Celgene´s EMEA headquarters; reveals how their workforce has increased from a handful of individuals in 2006 to 700 in Switzerland and 2,300 across Europe today; and how Celgene’s continuous R&D investment distinguishes…

Switzerland Prof. Dr. med. Adriano Aguzzi provides insight on the past, present, and future of prion and antibody therapy research in Switzerland. The Institute of Neuropathology works closely with the University Hospital of Zurich to conduct their research. He also touches on translating research to industry and his spinoff ImmunoQure, which…

Health Professor Jürg Utzinger of the Swiss Tropical and Public Health Institute (Swiss TPH) emphasizes the importance of partnerships and sharing information for improving population health locally, nationally, and internationally. He comments on Swiss innovation, the clinical trials conducted at Swiss TPH, and the current publicity around the Zika virus.   You…

Pharma Janssen Switzerland’s Ludo Ooms highlights the strengths of the Swiss healthcare and life sciences sector including the efficiency of the government, a productive and well trained workforce, the national pricing system, and the climate for innovation; all factors which make Switzerland a strategic market for Johnson & Johnson and Janssen.…

Pharma Professor Dr. Susan M. Gasser of the Friedrich Miescher Institute for Biomedical Research describes FMI’s fundamental connection between academia and industry in Switzerland, the effects of the foundation’s research, notably on Novartis, and future projects in the making. Could you begin by introducing both yourself and your institute to our…

Pharma Pfizer Switzerland’s Pamela Alexa discusses launching Xeljanz (tofacitinib), a treatment for adult patients with moderate to severe active rheumatoid arthritis, building upon Pfizer’s tradition of developing patient-centered therapies. She also discusses supporting research in Switzerland through the Pfizer Research Prize Foundation, which celebrates its 25th anniversary in 2016. What have…

Pharma Switzerland’s pharma industry is moving beyond staid conservatism and embracing risk in order to compete internationally and foster a new culture of innovation. Switzerland is frequently considered one of the most entrepreneurial and competitive countries in the world. As Thomas Cunei, secretary general of Interpharma, the association that represents 92…

Health In the year of Gen Suisse’s 25th anniversary, CEO Daniela Suter talks supporting dialogue between scientists and politicians on life sciences in Switzerland, educating the general population, the attractiveness of the Swiss community for scientists, and her goals for the future. Could you give our international viewers an overview of…

R&D Professor Dr. Robert Riener speaks about the much anticipated Cybathlon event and its importance to technology transfer, the Swiss education system’s ability to attract international talent, and his goals for the future. You have been leading the Department of Health Sciences and Technology at ETH Zurich since February 2016. Could…